… Conclusion We conclude that COVID-19+ patients with moderate or severe illness benefit …
anticoagulation and that apixaban has similar efficacy to enoxaparin in decreasing mortality in …

… trial, we analyzed the effect on mortality of anticoagulation therapy chosen in the first …
COVID-19+ patients with moderate or severe illness benefit from anticoagulation and that apixaban …

… Despite the versatile role of heparin as both an anticoagulant and an anti-inflammatory drug,
… hospitalized patients, observed that apixaban and enoxaparin had similar beneficial effects …

… /h or greater with or without a heparin bolus of 80 units/kg with … 30 mL/min), or DOAC (Apixaban
10 mg twice daily, or 5 mg … heparin may have therapeutic effect in COVID-19 beyond its …

… mortality among patients with COVID-19-induced coagulopathy administered prophylactic
anticoagulation therapy with unfractionated heparin (… to apixaban from UFH or enoxaparin due …

… impact of anticoagulation on the in-hospital mortality and bleeding risk of inpatients with
COVID-19. … regimen (prophylactic/therapeutic dose of apixaban, enoxaparin, and heparin) with a …

… -day mortality was seen between patients receiving heparin … , heparin therapy was associated
with lower 28-day mortality (… enoxaparin or apixaban are superior to a prophylactic dose of …

… therapeutic dose anticoagulation with a heparin formulation … in mortality in ICU COVID-19
patients over no anticoagulation in … COVID) comparing enoxaparin with apixaban in this patient …

… between apixaban/enoxaparin/aspirin and lower mortality … of therapeutic-dose anticoagulation
with heparin versus usual … COVID-19, our study showed that the use of apixaban, …

… studies observing impact of AC on COVID-19 mortality. The … molecular weight heparin (LMWH)
or unfractionated heparin (… other than apixaban 15,40 in COVID-19 population are lacking…